A share price of Corcept Therapeutics Inc [CORT] is currently trading at $90.32, up 0.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CORT shares have gain 8.68% over the last week, with a monthly amount glided 26.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
Corcept Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $42.01 and $117.33. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $90.32 at the most recent close of the market. An investor can expect a potential return of 55.0% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Trailing Twelve Months sales for Corcept Therapeutics Inc [NASDAQ:CORT] were 716.08M which represents 18.70% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.2 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 89.48 points at the first support level, and at 88.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 90.74, and for the 2nd resistance point, it is at 91.16.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Corcept Therapeutics Inc [NASDAQ:CORT] is 3.06. Further, the Quick Ratio stands at 2.98, while the Cash Ratio is 0.71. Considering the valuation of this stock, the price to sales ratio is 13.29, the price to book ratio is 14.96 and price to earnings (TTM) ratio is 80.38.
Transactions by insiders
Recent insider trading involved Guyer William, Officer, that happened on Oct 07 ’25 when 20000.0 shares were purchased. Chief Executive Officer, BELANOFF JOSEPH K completed a deal on Oct 01 ’25 to sell 40000.0 shares. Meanwhile, Lyon Joseph Douglas sold 5000.0 shares on Oct 01 ’25.
